With nearly €4 billion of capital investment in large molecule manufacturing underway, Ireland’s strategy to become a premier destination for biologics FDI has proven to be successful, according to BioPharmaChem Ireland director Matt Moran. Yet, Ireland today is much more than a manufacturing hub, and is well on its way to being a true innovative center of excellence for the global pharmaceutical industry as a whole.
It’s been nearly four years since you were last interviewed by PharmaBoardroom -what would you highlight as the most significant changes in the Irish pharma industry since then?
The primary change has been the explosion of investment within the biologics segment of the industry.
